Top

Published in:

24-06-2023 | Breast Cancer

Current Recommendations and Role of Breast Conservation Surgery for Multifocal or Multicentric Breast Cancer

Authors: Quratulain Anna Sabih, Kristin M. Lupinacci, Emilia J. Diego

Published in: Current Breast Cancer Reports | Issue 3/2023

Abstract

Purpose of Review

With improvements in imaging, breast cancers are diagnosed at earlier stages and increasingly, with additional findings of multifocal or multicentric disease. The aim of this review is to challenge existing paradigms that these scenarios can only be addressed with a mastectomy.

Recent Findings

Traditionally, multifocal or multicentric breast cancers have been addressed with a total mastectomy. Partial mastectomies have been attempted with the tacit understanding between patient and physician that the intervening tissue between cancer foci may contain cancer, and the safest oncologic decision would be to include the interposed tissue during surgical resection. More recent studies have refuted these long-held beliefs. This review is completed to bring to the fore the safety of breast conserving surgery in this population and data supporting this practice.

Summary

Multifocal and multicentric breast cancers can be surgically treated with breast conserving surgery, with no difference in oncologic outcomes if negative margins are obtained.

Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1–2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979–90. https://doi.org/10.1002/1097-0142(19850901)56:5%3c979::aid-cncr2820560502%3e3.0.co;2-n.CrossRefPubMed

Vlastos G, et al. Impact of multicentricity on clinical outcome in patients with T1–2, N0–1, M0 breast cancer. Ann Surg Oncol. 2000;7(8):581–7. https://doi.org/10.1007/BF02725337.CrossRefPubMed

Gentilini O, et al. Conservative surgery in patients with multifocal/multicentric breast cancer. Breast Cancer Res Treat. 2009;113(3):577–83. https://doi.org/10.1007/s10549-008-9959-7.CrossRefPubMed

Patani N, Carpenter R. Oncological and aesthetic considerations of conservational surgery for multifocal/multicentric breast cancer. Breast J. 2010;16(3):222–32. https://doi.org/10.1111/j.1524-4741.2010.00917.x.CrossRefPubMed

Cho LC, Senzer N, Peters GN. Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers. Am J Surg. 2002;183(6):650–4. https://doi.org/10.1016/s0002-9610(02)00864-4.CrossRefPubMed

Kurtz JM, et al. Breast-conserving therapy for macroscopically multiple cancers. Ann Surg. 1990;212(1):38–44. https://doi.org/10.1097/00000658-199007000-00006.CrossRefPubMedCentralPubMed

Leopold KA, et al. Results of conservative surgery and radiation therapy for multiple synchronous cancers of one breast. Int J Radiat Oncol Biol Phys. 1989;16(1):11–6. https://doi.org/10.1016/0360-3016(89)90004-7.CrossRefPubMed

Wilson LD, Beinfield M, McKhann CF, Haffty BG. Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer. 1993;72(1):137–42. https://doi.org/10.1002/1097-0142(19930701)72:1%3c137::aid-cncr2820720126%3e3.0.co;2-e.CrossRefPubMed

Comber KR, Merrikin DJ, Sutherland R. Antibacterial activity and synergy, in vitro and in vivo, of a combination of amoxycillin and flucloxacillin. Chemotherapy. 1979;25(1):30–9. https://doi.org/10.1159/000237819.CrossRefPubMed

10.••

Lorenzi De, et al. Oncoplastic breast-conserving surgery for synchronous multicentric and multifocal tumors: is it oncologically safe? A retrospective matched-cohort analysis. Ann Surg Oncol. 2022;29(1):427–36. https://doi.org/10.1245/s10434-021-10800-w. This Italian study is the most current data till date. The study follows retrospective matched cohorts of multicentric and multifocal cancer patients, treated with breast conserving surgery vs. mastectomy. This most recent iteration of the study reinforces that the outcomes for the two groups are similar, further strengthening the case for breast conservation in these patients.CrossRefPubMed

11.

Winters ZE, et al. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open. 2018;2(4):162–74. https://doi.org/10.1002/bjs5.53.CrossRefPubMedCentralPubMed

12.

Lim W, et al. Breast conserving surgery for multifocal breast cancer. Ann Surg. 2009;249(1):87–90. https://doi.org/10.1097/SLA.0b013e31818e41c0.CrossRefPubMed

13.

Kaplan J, Giron G, Tartter PI, Bleiweiss IJ, Estabrook A, Smith SR. Breast conservation in patients with multiple ipsilateral synchronous cancers. J Am Coll Surg. 2003;197(5):726–9. https://doi.org/10.1016/j.jamcollsurg.2003.06.003.CrossRefPubMed

14.

Boughey JC et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance). J Clin Oncol. 2023:JCO2202553. https://doi.org/10.1200/JCO.22.02553.

15.

Wilkinson LS, Given-Wilson R, Hall T, Potts H, Sharma AK, Smith E. Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound. Clin Radiol. 2005;60(5):573–8. https://doi.org/10.1016/j.crad.2004.10.015.CrossRefPubMed

16.

Sardanelli F, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol. 2004;183(4):1149–57. https://doi.org/10.2214/ajr.183.4.1831149.CrossRefPubMed

17.•

Laas, El Beheiry M, Masson JB, Malhaire C. Partial breast resection for multifocal lower quadrant breast tumour using virtual reality. BMJ Case Rep. 2021;14(3). https://doi.org/10.1136/bcr-2021-241608. This case report shows a novel approach of using technology to more accurately measure breast and tumor volumes. This accuracy can further help surgeons determine which patients will tolerate breast conservative surgery even with multifocal and multicentric cancers.

18.

Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol. 2005;23(30):7497–502. https://doi.org/10.1200/JCO.2005.02.1147.CrossRefPubMed

19.

Weissenbacher TM, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010;122(1):27–34. https://doi.org/10.1007/s10549-010-0917-9.CrossRefPubMed

20.

Cabioglu N, et al. Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg. 2009;208(1):67–74. https://doi.org/10.1016/j.jamcollsurg.2008.09.001.CrossRefPubMed

21.•

Onisai et al. Synchronous multiple breast cancers-do we need to reshape staging?. Medicina (Kaunas). 2020;56(5). https://doi.org/10.3390/medicina56050230. This European study proposes revisiting the staging scheme for Multifocal and Multicentric breast cancers to be more focused on the characteristics of the most aggressive tumor and not the size.

22.

Pawloski KR, Tadros AB, El-Tamer M. ASO author reflections: age is an important determinant of concordance between 21-Gene recurrence scores in multiple ipsilateral breast carcinomas. Ann Surg Oncol. 2021;28(8):4263–4. https://doi.org/10.1245/s10434-020-09443-0.CrossRefPubMedCentralPubMed

23.•

Pawloski, Wen HY, Tadros AB, Abbate K, Morrow M, El-Tamer M. Concordance between 21-Gene recurrence scores in multifocal or multicentric breast carcinomas differs by age and histologic subtype. Ann Surg Oncol. 2021;28(8):4256–62. https://doi.org/10.1245/s10434-020-09429-y. This very important study guides us to use Recurrence scores for all tumors in patients with multicentric and multifocal breast cancers who are under the age of 50. Much like the TailorX study, age younger than 50 is found to be significant factor for Multifocal and Multicentric cancers and recurrence scores in addition to unifocal cancers.

24.

Sorscher S. Significance of 21-Gene non-concordant recurrence scores in patients with multifocal or multicentric breast carcinomas. Ann Surg Oncol. 2021;28(Suppl 3):791–2. https://doi.org/10.1245/s10434-021-10918-x.CrossRefPubMed

25.

Altundag K. Multicentric ipsilateral invasive breast carcinomas might have higher 21-Gene recurrence score compared with multifocal ipsilateral invasive breast carcinomas. Ann Surg Oncol. 2019;26(1):309. https://doi.org/10.1245/s10434-018-7077-2.CrossRefPubMed

26.

Grabenstetter A, et al. Reply to “Multicentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomas.” Ann Surg Oncol. 2019;26(1):310–1. https://doi.org/10.1245/s10434-018-7078-1.CrossRefPubMed

27.

Okumura S, et al. Feasibility of breast-conserving therapy for macroscopically multiple ipsilateral breast cancer. Int J Radiat Oncol Biol Phys. 2004;59(1):146–51. https://doi.org/10.1016/j.ijrobp.2003.09.088.CrossRefPubMed

28.

Oh JL, et al. Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol. 2006;24(31):4971–5. https://doi.org/10.1200/JCO.2006.07.6067.CrossRefPubMed

29.

Nos C et al. [Conservative treatment of multifocal breast cancer: a comparative study]. Bull Cancer. 1999;86(2):184–8. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/10066949. Accessed 29 Apr 2023. Traitement conservateur des cancers du sein multifocaux: etude a propos de 56 cas traites a l'Institut Curie de 1983 a 1989.

30.

Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32. https://doi.org/10.1056/NEJMoa020989.CrossRefPubMed

31.

Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41. https://doi.org/10.1056/NEJMoa022152.CrossRefPubMed

32.

Chatterjee A. Editorial on oncoplastic breast-conserving surgery for synchronous multicentric and multifocal tumors: is it oncologically safe? A retrospective matched-cohort analysis. Ann Surg Oncol. 2022;29(1):23–4. https://doi.org/10.1245/s10434-021-10919-w.CrossRefPubMed

33.

Young AE. Quadrantectomy for early breast cancer. Br J Surg. 1991;78(4):387. https://doi.org/10.1002/bjs.1800780403.CrossRefPubMed

34.

Aspegren K, Holmberg L, Adami HO. Standardization of the surgical technique in breast-conserving treatment of mammary cancer. Br J Surg. 1988;75(8):807–10. https://doi.org/10.1002/bjs.1800750829.CrossRefPubMed

35.

Kawamoto H, Ogata H, Ohta T, Fukuda M. [Breast-conserving surgery: quadrantectomy]. Nihon Geka Gakkai Zasshi. 2002;103(11): 811–5. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/12478857. Accessed 29 Apr 2023

36.

Galimberti V, et al. Central small size breast cancer: how to overcome the problem of nipple and areola involvement. Eur J Cancer. 1993;29A(8):1093–6. https://doi.org/10.1016/s0959-8049(05)80294-1.CrossRefPubMed

37.

Pezzi CM, Kukora JS, Audet IM, Herbert SH, Horvick D, Richter MP. Breast conservation surgery using nipple-areolar resection for central breast cancers. Arch Surg. 2004;139(1):32–7. https://doi.org/10.1001/archsurg.139.1.32. (discussion 38).CrossRefPubMed

38.

Guirguis MS, et al. Bracketing with multiple radioactive seeds to achieve negative margins in breast conservation surgery: multiple seeds in breast surgery. Clin Breast Cancer. 2022;22(2):e158–66. https://doi.org/10.1016/j.clbc.2021.05.013.CrossRefPubMed

39.

Veronesi U, et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer. 1990;26(6):671–3. https://doi.org/10.1016/0277-5379(90)90114-9.CrossRefPubMed

40.

Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer. 2004;100(1):20–7. https://doi.org/10.1002/cncr.11880.CrossRefPubMed

41.

Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher DW. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer. 2002;94(5):1383–90. https://doi.org/10.1002/cncr.10331.CrossRefPubMed

42.

Gentilini O, et al. Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur J Surg Oncol. 2006;32(5):507–10. https://doi.org/10.1016/j.ejso.2006.02.018.CrossRefPubMed

43.

Schwartz GF, Giuliano AE, Veronesi U, C. Consensus Conference. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94(10):2542–51. https://doi.org/10.1002/cncr.10539.CrossRefPubMed

44.

Jin Kim H, Heerdt AS, Cody HS, Van Zee KJ. Sentinel lymph node drainage in multicentric breast cancers. Breast J. 2002;8(6):356–61. https://doi.org/10.1046/j.1524-4741.2002.08605.x.CrossRefPubMed

45.

Tousimis E, et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J Am Coll Surg. 2003;197(4):529–35. https://doi.org/10.1016/S1072-7515(03)00677-X.CrossRefPubMed

46.

Ferrari A, et al. Multifocality and multicentricity are not contraindications for sentinel lymph node biopsy in breast cancer surgery. World J Surg Oncol. 2006;4:79. https://doi.org/10.1186/1477-7819-4-79.CrossRefPubMedCentralPubMed

47.

Zavagno G, et al. Axillary sentinel lymph nodes in breast cancer: a single lymphatic pathway drains the entire mammary gland. Eur J Surg Oncol. 2005;31(5):479–84. https://doi.org/10.1016/j.ejso.2005.03.001.CrossRefPubMed

48.

Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg. 2000;232(1):81–9. https://doi.org/10.1097/00000658-200007000-00012.CrossRefPubMedCentralPubMed

49.

Hudson DA. A modified excision for combined reduction mammoplasty and breast conservation therapy in the treatment of breast cancer. Aesthetic Plast Surg. 2007;31(1):71–5. https://doi.org/10.1007/s00266-005-0063-7.CrossRefPubMed

50.

McCulley SJ, Macmillan RD. Planning and use of therapeutic mammoplasty–Nottingham approach. Br J Plast Surg. 2005;58(7):889–901. https://doi.org/10.1016/j.bjps.2005.03.008.CrossRefPubMed

51.

Jones JA, Pu LL. Oncoplastic approach to early breast cancer in women with macromastia. Ann Plast Surg. 2007;58(1):34–8. https://doi.org/10.1097/01.sap.0000250754.73886.0c.CrossRefPubMed

52.

Crown A, Laskin R, Rocha FG, Grumley J. Extreme oncoplasty: Expanding indications for breast conservation. Am J Surg. 2019;217(5):851–6. https://doi.org/10.1016/j.amjsurg.2019.01.004.CrossRefPubMed

53.

Silverstein MJ, Savalia N, Khan S, Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. Breast J. 2015;21(1):52–9. https://doi.org/10.1111/tbj.12356.CrossRefPubMed

54.

AceaNebril B, Garcia Novoa A, Polidorio N, CereijoGarea C, Bouzon Alejandro A, Mosquera Oses J. Extreme oncoplasty: The last opportunity for breast conservation-Analysis of its impact on survival and quality of life. Breast J. 2019;25(3):535–6. https://doi.org/10.1111/tbj.13267.CrossRef

55.

Kronowitz SJ, et al. Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg. 2006;117(1):1–11. https://doi.org/10.1097/01.prs.0000194899.01875.d6. (discussion 12-4).CrossRefPubMed

56.

Clough KB, Kroll SS, Audretsch W. An approach to the repair of partial mastectomy defects. Plast Reconstr Surg. 1999;104(2):409–20. https://doi.org/10.1097/00006534-199908000-00014.CrossRefPubMed

57.

Asgeirsson KS, Rasheed T, McCulley SJ, Macmillan RD. Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol. 2005;31(8):817–23. https://doi.org/10.1016/j.ejso.2005.05.010.CrossRefPubMed

58.

Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques. Lancet Oncol. 2005;6(3):145–57. https://doi.org/10.1016/S1470-2045(05)01765-1.CrossRefPubMed

59.

Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol. 2010;17(5):1375–91. https://doi.org/10.1245/s10434-009-0792-y.CrossRefPubMed

60.

Santanelli F, Paolini G, Longo B. Comments on: Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery (Clough KB, Kaufman GJ, et al. ASO DOI 10.1245/s10434-009-0792-y). Ann Surg Oncol. 2011;18 Suppl 3:S257-8. https://doi.org/10.1245/s10434-010-1301-z. (author reply S259-60).CrossRefPubMed

61.

Kronowitz SJ, et al. Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg. 2007;120(7):1755–68. https://doi.org/10.1097/01.prs.0000287130.77835.f6.CrossRefPubMed

62.

Kronowitz SJ, Kuerer HM, Buchholz TA, Valero V, Hunt KK. A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. Plast Reconstr Surg. 2008;122(6):1631–47. https://doi.org/10.1097/PRS.0b013e31818cbf1b.CrossRefPubMed

63.•

McCrorie, et al. Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers. J Pathol Clin Res. 2020;6(2):146–53. https://doi.org/10.1002/cjp2.155. BRCA 2 mutation carriers have been found to have 4 fold increased incidence of Multifocal and Multicentric breast cancers as when compared to BRCA 1 patients.

64.

Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know. Ann Ital Chir. 2019;90:1–2. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/30872561. Accessed 29 Apr 2023

65.

Biglia N, D'Alonzo M, Sgro LG, Tomasi Cont N, Bounous V, Robba E. Breast cancer treatment in mutation carriers: surgical treatment. Minerva Ginecol. 2016;68(5):548–56, Oct. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/26822896. Accessed 29 April 2023

66.

Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443–55. https://doi.org/10.1007/s10549-014-2890-1.CrossRefPubMed

67.

Vallard A, et al. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist’s point of view. Br J Radiol. 2019;92(1097):20170657. https://doi.org/10.1259/bjr.20170657.CrossRefPubMedCentralPubMed

68.

Pierce LJ, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389–98. https://doi.org/10.1007/s10549-010-0894-z.CrossRefPubMedCentralPubMed

69.

Rosenkranz KM, et al. The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) trial. Ann Surg Oncol. 2018;25(10):2858–66. https://doi.org/10.1245/s10434-018-6583-6.CrossRefPubMed

70.

Boughey KRJ, Ballman K, McCall L, Haffty B, Cuttino L, Kubicky C, Le-Petross C, Giuliano A, Van Zee K, Hunt K, Hahn O, Carey L, Partridge A, –” . "“Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer," San Antonino Breast Cancer Symposium, Dec 2022. Results from ACOSOG Z11102 (Alliance).

71.•

Rosenkranz, et al. Cosmetic outcomes following breast-conservation surgery and radiation for multiple ipsilateral breast cancer: data from the alliance Z11102 study. Ann Surg Oncol. 2020;27(12):4650–61. https://doi.org/10.1245/s10434-020-08893-w. Prospectively patients from the Z 11 trial were followed for cosmetic outcomes for multifocal and multicentric breast cancer patients. The results based on a 4 point cosmetic survey showed equivalent results to unifocal breast cancers.

72.

Cuttino LW, et al. The feasibility of radiation therapy after breast-conserving surgery for multiple ipsilateral breast cancer: an initial report from ACOSOG Z11102 (Alliance) trial. Int J Radiat Oncol Biol Phys. 2022;112(3):636–42. https://doi.org/10.1016/j.ijrobp.2021.09.054.CrossRefPubMed

73.•

Masannat, et al. Global variations in the definition and management of multifocal and multicentric breast cancer: the MINIM international survey. Br J Surg. 2022;109(8):656–9. https://doi.org/10.1093/bjs/znac080. This very important study looking at data from over 100 countries helps us to see the increasing trend for breast conservation surgery. Even when accounting for some limitations or resources, differences in practices and patient population, multifocal cancers is now uniformaly treated with breast conservation surgery. The trend for multicentric cancers shows similar change but there is a lag in adapting this technique across various countries for a myriad of reasons.

74.•

Dal, et al. Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers? Rev Assoc Med Bras. 1992;68(3):405–12. https://doi.org/10.1590/1806-9282.20211168. This study shows that even though focal heterogeneity seen in the different cancers in multifocal and multicentric disease have a bearing on some local and systemic therapy changes, the over all outcome, recurrence and survival are not effected.

75.

Tong Y, Sun F, Zhang C, Yang S, Yu Z, Zhao Y. Multifocal/multicentric breast cancer: Does each focus matter? Cancer Med. 2023. https://doi.org/10.1002/cam4.5626.

Title: Current Recommendations and Role of Breast Conservation Surgery for Multifocal or Multicentric Breast Cancer
Authors: Quratulain Anna Sabih
Kristin M. Lupinacci
Emilia J. Diego
Publication date: 24-06-2023
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Mastectomy
Published in: Current Breast Cancer Reports / Issue 3/2023
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-023-00494-2

Practical Approach to Establishing a Lymphedema Screening Program: Tips and Tricks

Lymphedema

The Future of Lymphedema: Potential Therapeutic Targets for Treatment

Lymphedema

Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities

Open Access
Breast Cancer

Clinical Applications for Liquid Biopsy Assessment of Minimal Residual Disease in Breast Cancer

Breast Cancer

Postmastectomy Radiation Modalities (Protons, Chest Wall Boost, Skin Bolus, Fractionation, and Timing) and Breast Reconstruction Complications: The Role of Radiation Oncologist

Mastectomy

Regional Nodal Irradiation and Post-Mastectomy Radiation Therapy After Up-Front Surgery

Mastectomy

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Podcast | Sexual health in older age

Springer Medicine

Current Recommendations and Role of Breast Conservation Surgery for Multifocal or Multicentric Breast Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Other articles of this Issue 3/2023

Practical Approach to Establishing a Lymphedema Screening Program: Tips and Tricks

The Future of Lymphedema: Potential Therapeutic Targets for Treatment

Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities

Clinical Applications for Liquid Biopsy Assessment of Minimal Residual Disease in Breast Cancer

Postmastectomy Radiation Modalities (Protons, Chest Wall Boost, Skin Bolus, Fractionation, and Timing) and Breast Reconstruction Complications: The Role of Radiation Oncologist

Regional Nodal Irradiation and Post-Mastectomy Radiation Therapy After Up-Front Surgery

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Podcast | Sexual health in older age

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content